Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of which ...
If you or a loved one has gallbladder or bile duct cancer, you may be interested in learning more about treatments for it. For a long time, the standard treatment options for this cancer type were ...
Real-world data on the effectiveness and toxicity of atezolizumab and bevacizumab as first-line therapy in patients with unresectable or metastatic hepatocellular carcinoma in Costa Rica. Efficacy and ...
A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB). This is an ASCO Meeting ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...
Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
A biliary stent is a small tube that a doctor inserts into the liver to allow bile to drain typically and relieve symptoms of a blocked bile duct. A blocked bile duct may occur with liver cancer and ...
A bile duct drain, also called biliary drainage, can help treat blocked bile ducts so that bile may flow as it should, helping your liver digest fats. Learn more about biliary drainage, including how ...
There has not been a change in the standard of care in this type of cancer in a decade, according to an expert from ASCO. Pairing durvalumab (Imfinzi) with the chemotherapy combination gemcitabine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results